


NCCN Guidelines Update NSCLC: IMFINZI® is recommended after **concurrent and sequential CRT¹**



CH-9192\_XRA\_02/2024

\* For patients who have received sequential chemoradiation, IMFINZI® can be considered as consolidation immunotherapy.<sup>1</sup>

Adapted from Ettinger DS, et al. NCCN Guidelines, NSCLC, Version 1.2024.<sup>1</sup>

Summary of updated NCCN recommendations:<sup>1</sup>

- The NCCN NSCLC Panel **recommends IMFINZI® (category 1) as a consolidation immunotherapy option** (regardless of PD-L1 status) for eligible patients (PS 0–1) with unresectable stage III NSCLC and without disease progression after treatment with definitive concurrent platinum-based chemoradiation
- Sequential chemoradiation or radiation therapy alone is appropriate for frail patients unable to tolerate concurrent therapy
- For patients who have received **sequential chemoradiation**, IMFINZI® can be considered as consolidation immunotherapy

**PACIFIC-6 and PACIFIC-R study results strongly contributed to the NCCN Guidelines Update on stage III NSCLC:<sup>1-4</sup>**

- IMFINZI®: **Sustained 5-year OS and PFS benefit with 28% reduction in risk of mortality<sup>2</sup>**
- RWE showing an **improvement in PFS and OS** comparable to the PACIFIC trial after **concurrent and sequential CRT<sup>2,3</sup>**
- **Good tolerability and encouraging efficacy** of IMFINZI® after **sequential CRT<sup>4</sup>**

CRT: chemoradiation; NCCN: National Comprehensive Cancer Network; NSCLC: Non-Small Cell Lung Cancer; OS: overall survival; PD-L1: programmed death ligand 1; PFS: progression-free survival; PS: performance status; RWE: real-world evidence; sCRT: sequential chemoradiation.

References:

1. Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 1.2024, NCCN Clinical Practice Guidelines in Oncology.  
2. Spigel DR, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 20;40(12):1301-1311.  
3. Girard N, et al. Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small-cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study. Immuno-Oncology and Technology. 2022; 16: 100163.  
4. Garassino MC, et al. Durvalumab after sequential chemoradiotherapy in patients with unresectable Stage III NSCLC: Final analysis from PACIFIC 6. Presentation LBA61, ESMO Congress 2023. Madrid, Spain, 20-24 October 2023.